Loading
CABONE showed that the tablet cabozantinib could shrink or hold back both Ewing sarcoma and osteosarcoma that had come back after standard chemotherapy, the first drug to show meaningful activity in both bone cancers.
CABONE was a French multicentre phase 2 study of cabozantinib, an inhibitor of MET, VEGF receptors and other kinases, in 90 patients aged 12 or older with advanced Ewing sarcoma or osteosarcoma after standard therapy. The primary endpoint was objective response at six months in the Ewing cohort and objective response or six-month non-progression in the osteosarcoma cohort.
Both cohorts met their predefined activity thresholds, with objective responses in Ewing sarcoma and a high rate of six-month non-progression in osteosarcoma. Toxicity was consistent with cabozantinib in adults, including pneumothorax in some patients with lung metastases. Cabozantinib is now used off-label at relapse and is being tested in combinations in paediatric bone sarcoma trials.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
90 enrolled.
95% CI 13 to 42; all partial responses; median follow-up 31.3 months
Source95% CI 4 to 26; all partial responses
Source95% CI 20 to 50
SourceShares Ewing sarcoma, Osteosarcoma, Anti-angiogenic therapy, Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Ewing sarcoma, Osteosarcoma, Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Anti-angiogenic therapy, Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy and the tag subtype-trials.